eyesON | Phase II Vanguards
Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
In our community learning session with Giray Görbil (Clinical Marketing Coordinator at Cyntegrity), we explored the fascinating connection between the "Law of Attraction and the Power of Imagination". These two concepts, when combined, can unlock new ways of thinking, creating, and shaping our personal [...]
In today’s global market, success isn’t just about offering a great product or service it’s about connecting with people from different cultures in a meaningful way. The latest Community Learning Session with Julien Goncalves (Head of Growth at Cyntegrity) shared valuable insights during his [...]
Join Cyntegrity at the ACDM RBQM Symposium 2025 in Amsterdam! Don’t miss Johann Proeve’s expert talk on ICH E6(R3), E8(R1), and CDM evolution.
Join Cyntegrity at SCOPE 2025 Barcelona, Booth #4, and explore how AI-powered RBQM cuts review cycles by 30% and boosts inspection readiness.
Download our DIA 2025 posters and see how upfront RBQM—applied to rare-disease trials and joint CRF design—sharpens data quality, elevates patient safety, and keeps studies ICH E6(R3)-ready.
Learn how audit trails strengthen RBQM in clinical trials with insights from guest speaker Nechama Katan, (Chief Wicked Problem Wizard.)
Join our hands-on online RBQM & QbD short course at DIA 2025 on June 10. Learn to assess risks, define KRIs/QTLs, and apply ICH E6(R2/R3).
Learn from guest speakers Prof. Dr. Kai Eckert (Mannheim University of Applied Sciences) & Andrew Warrington (Microsoft) how to ensure trustworthy AI.
Join Cyntegrity & Microsoft in Frankfurt for a leadership roundtable on AI & QbD with guest speaker Andrew Warrington, (Senior Industry Advisor.)
Join Cyntegrity at the ACDM Symposium in Frankfurt, where our CEO Artem Andrianov will discuss AI-TRIAL’s role in transforming clinical trial management.